OR WAIT null SECS
July 26, 2024
Article
A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.
Video
In this part of our 5-part series, Gus Alva, MD discusses the next steps in research for long-term effects and broader applications of MDMA-assisted therapy.
In this part of our 5-part series, Gus Alva, MD explores MDMA’s neurochemical impact and the need for ongoing research.
In this part of our 5-part series, Gus Alva, MD highlights the importance of education and overcoming skepticism about MDMA-assisted therapy.
In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.
In this part of our 5-part series, Gus Alva, MD discusses the unmet need in PTSD treatment and the potential of MDMA-assisted therapy.
July 06, 2024
Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.
July 03, 2024
Dunlop provided his opinions on the committee’s comments regarding functional unblinding and cardiovascular implicative risks when it comes to studying MDMA.
July 01, 2024
Family physician Scuderi shares how he helps patients manage PTSD symptoms ahead of Fourth of July fireworks.
June 25, 2024
FDA accepts a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, with a PDUFA date of February 8, 2025.